The New England journal of medicine, 2017-12, Vol.377 (26), p.2545-2554
2017
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
- Ist Teil von
- The New England journal of medicine, 2017-12, Vol.377 (26), p.2545-2554
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2017
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- Among 38 patients with refractory diffuse large B-cell lymphoma or follicular lymphoma, 28 were able to receive CAR T cells; 16 had complete remission, and none of those who had had a complete response at 6 months had a relapse at 28 months of follow-up.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa1708566Titel-ID: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5788566
- Format
- –
- Schlagworte
- Adult, Aged, Antigens, Antigens, CD19, Autografts, B-cell lymphoma, B-Lymphocytes - immunology, Biomarkers - analysis, Bone marrow, CD19 antigen, Chemotherapy, Chimeric antigen receptors, Disease-Free Survival, Drug dosages, Encephalopathy, FDA approval, Female, Humans, Immunoglobulin A, Immunoglobulin G, Immunoglobulin M, Immunotherapy, Adoptive, Leukemia, Lymphocytes, Lymphocytes B, Lymphocytes T, Lymphoma, Lymphoma, Follicular - mortality, Lymphoma, Follicular - therapy, Lymphoma, Large B-Cell, Diffuse - mortality, Lymphoma, Large B-Cell, Diffuse - therapy, Male, Medical prognosis, Middle Aged, Patients, Receptors, Antigen, T-Cell - therapeutic use, Remission, Remission Induction, Signal transduction, Survival Analysis, T-Lymphocytes - immunology, Transplantation